PROMISE
Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)
What will happen during the trial?
The goal of the PROMISE research study is to determine clinical/genomic alterations present in individuals with MGUS and SMM, who are diagnosed though screening of a high-risk population. We also seek to determine clinical/genomic/epigenetic and immune environmental predictors of progression to multiple myeloma in patients with MGUS and SMM.
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Observational Trial
- Enrollment
- 30,000 patients (estimated)
- Sponsors
- Dana-Farber Cancer Institute
- Collaborators
- Stand Up To Cancer
- Tags
- High Risk, Observational, Participate From Home
- Trial Type
- Observational
- Last Update
- 1 month ago
- SparkCures ID
- 979
- NCT Identifier
- NCT03689595
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.